
1. j antimicrob chemother. 2018 jan 1;73(1):173-176. doi: 10.1093/jac/dkx366.

no impact hiv-1 protease minority resistant variants virological
response first-line pi-based regimen containing darunavir atazanavir.

perrier m(1), visseaux b(1), landman r(2), joly v(2), todesco e(3)(4),
yazdanpanah y(2), calvez v(3)(4), marcelin ag(3)(4), descamps d(1), charpentier
c(1).

author information: 
(1)iame, umr 1137, inserm, université paris diderot, sorbonne paris cité, ap-hp, 
laboratoire de virologie, hôpital bichat, ap-hp, paris, france.
(2)iame, umr 1137, inserm, université paris diderot, sorbonne paris cité, ap-hp, 
service de maladies infectieuses et tropicales, hôpital bichat, ap-hp, paris,
france.
(3)sorbonne university, upmc univ. paris 06, inserm, institut pierre louis
d'épidémiologie et de santé publique (iplesp umrs 1136), paris, france.
(4)department virology, pitié-salpêtrière hospital, ap-hp, paris, france.

objectives: evaluate, clinical cohort hiv-1-infected patients, the
prevalence pi minority resistant variants (mrv) art baseline their
impact virological response first-line pi-based regimen.
patients methods: observational single-centre cohort, assessed all
art-naive patients initiating first-line regimen including two nrti one
boosted pi, darunavir/ritonavir atazanavir/ritonavir, january 2012 and
march 2015. ultra-deep sequencing pol gene performed using illumina®
technology. protease mutations identified using transmitted drug
resistance list major pi resistance mutations (ias-usa drug resistance
mutations list).
results: ninety-four 16 patients initiating darunavir/ritonavir-based
regimen atazanavir/ritonavir-based regimen, respectively, assessed.
twenty-eight percent patients hiv-1 subtype b, 39% crf02_ag 33%
other non-b subtypes. thirteen patients (13.8%) darunavir group three 
patients (18.8%) atazanavir group experienced virological failure (vf). 
overall, 13 (11.8%) subjects pi mrv baseline median proportion of
1.3% (iqr = 1.1-1.7). prevalent pi mrv g73c (n = 5) m46i
(n = 3). proportion patients harbouring baseline pi mrv similar
between virological success (10.6%) experiencing vf (18.8%) 
(p = 0.40). difference observed rate pi mrv viral subtype
(p = 0.51) pi drug (p = 0.40).
conclusions: study showed prevalence 11.8% pi mrv among 110
art-naive subjects, without significant impact virological response a
first-line pi-based regimen containing darunavir atazanavir.

© author 2017. published oxford university press behalf british 
society antimicrobial chemotherapy. rights reserved. permissions,
please email: journals.permissions@oup.com.

doi: 10.1093/jac/dkx366 
pmid: 29077926  [indexed medline]

